Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signaling

Molecular Immunology

Volumn 51, Issue 1, 2012, Pages 91-100

  Pahl, Jens H W ^a   Verhoeven, Dirk H J ^a   Kwappenberg, Kitty M C ^a   Vellinga, Jort ^b   Lankester, Arjan C ^a   van Tol, Maarten J D ^a   Schilham, Marco W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Adenovirus; Interferon ; NK cells; Plasmacytoid dendritic cells; TLR9

Indexed keywords

ALPHA INTERFERON; CD56 ANTIGEN; CD69 ANTIGEN; INTERLEUKIN 2; TOLL LIKE RECEPTOR 9;

ADENOVIRUS; ADENOVIRUS 35; ADENOVIRUS 5; ARTICLE; CELL ACTIVATION; CELL MATURATION; CELL STIMULATION; CYTOKINE PRODUCTION; CYTOLYSIS; DOWN REGULATION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; NONHUMAN; NORMAL HUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SEROTYPE; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS LOAD;

ADENOVIRUSES, HUMAN; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL COMMUNICATION; DENDRITIC CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 9;

ADENOVIRIDAE; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 5;

EID: 84859581254     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.02.119     Document Type: Article

References (67)

1. Asselin-Paturel C., Brizard G., Chemin K., Boonstra A., O'Garra A., Vicari A., Trinchieri G. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J. Exp. Med. 2005, 201:1157-1167.
2. Baldwin A., Kingman H., Darville M., Foot A.B., Grier D., Cornish J.M., Goulden N., Oakhill A., Pamphilon D.H., Steward C.G., Marks D.I. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant. 2000, 26:1333-1338.
3. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
4. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
5. Barr D.P., Belz G.T., Reading P.C., Wojtasiak M., Whitney P.G., Heath W.R., Carbone F.R., Brooks A.G. A role for plasmacytoid dendritic cells in the rapid IL-18-dependent activation of NK cells following HSV-1 infection. Eur. J. Immunol. 2007, 37:1334-1342.
6. Basner-Tschakarjan E., Gaffal E., O'Keeffe M., Tormo D., Limmer A., Wagner H., Hochrein H., Tuting T. Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production. J. Gene Med. 2006, 8:1300-1306.
7. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 1999, 17:189-220.
8. Chakrabarti S., Mautner V., Osman H., Collingham K.E., Fegan C.D., Klapper P.E., Moss P.A., Milligan D.W. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002, 100:1619-1627.
9. Colonna M., Trinchieri G., Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 2004, 5:1219-1226.
10. Draghi M., Pashine A., Sanjanwala B., Gendzekhadze K., Cantoni C., Cosman D., Moretta A., Valiante N.M., Parham P. NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J. Immunol. 2007, 178:2688-2698.
11. Duncan S.J., Gordon F.C., Gregory D.W., McPhie J.L., Postlethwaite R., White R., Willcox H.N. Infection of mouse liver by human adenovirus type 5. J. Gen. Virol. 1978, 40:45-61.
12. Echavarria M. Adenoviruses in immunocompromised hosts. Clin. Microbiol. Rev. 2008, 21:704-715.
13. Echavarria M., Forman M., van Tol M.J., Vossen J.M., Charache P., Kroes A.C. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001, 358:384-385.
14. Eggerding F.A., Pierce W.C. Molecular biology of adenovirus type 2 semipermissive infections. I. Viral growth and expression of viral replicative functions during restricted adenovirus infection. Virology 1986, 148:97-113.
15. Errington F., Steele L., Prestwich R., Harrington K.J., Pandha H.S., Vidal L., de Bono J., Selby P., Coffey M., Vile R., Melcher A. Reovirus activates human dendritic cells to promote innate antitumor immunity. J. Immunol. 2008, 180:6018-6026.
16. Eyrich M., Leiler C., Lang P., Schilbach K., Schumm M., Bader P., Greil J., Klingebiel T., Handgretinger R., Niethammer D., Schlegel P.G. A prospective comparison of immune reconstitution in pediatric recipients of positively selected CD34+ peripheral blood stem cells from unrelated donors vs recipients of unmanipulated bone marrow from related donors. Bone Marrow Transplant. 2003, 32:379-390.
17. Fehniger T.A., Cooper M.A., Nuovo G.J., Cella M., Facchetti F., Colonna M., Caligiuri M.A. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003, 101:3052-3057.
18. Feuchtinger T., Lucke J., Hamprecht K., Richard C., Handgretinger R., Schumm M., Greil J., Bock T., Niethammer D., Lang P. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br. J. Haematol. 2005, 128:503-509.
19. Flomenberg P., Babbitt J., Drobyski W.R., Ash R.C., Carrigan D.R., Sedmak G.V., McAuliffe T., Camitta B., Horowitz M.M., Bunin N., Casper J.T. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J. Infect. Dis. 1994, 169:775-781.
20. Flomenberg P., Piaskowski V., Truitt R.L., Casper J.T. Characterization of human proliferative T cell responses to adenovirus. J. Infect. Dis. 1995, 171:1090-1096.
21. Ganly I., Mautner V., Balmain A. Productive replication of human adenoviruses in mouse epidermal cells. J. Virol. 2000, 74:2895-2899.
22. Gerosa F., Gobbi A., Zorzi P., Burg S., Briere F., Carra G., Trinchieri G. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J. Immunol. 2005, 174:727-734.
23. Gilliet M., Cao W., Liu Y.J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 2008, 8:594-606.
24. Ginsberg H.S., Moldawer L.L., Sehgal P.B., Redington M., Kilian P.L., Chanock R.M., Prince G.A. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:1651-1655.
25. Grimm E.A., Mazumder A., Zhang H.Z., Rosenberg S.A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 1982, 155:1823-1841.
26. Guiducci C., Coffman R.L., Barrat F.J. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J. Intern. Med. 2009, 265:43-57.
27. Gursel I., Gursel M., Yamada H., Ishii K.J., Takeshita F., Klinman D.M. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J. Immunol. 2003, 171:1393-1400.
28. Havenga M., Vogels R., Zuijdgeest D., Radosevic K., Mueller S., Sieuwerts M., Weichold F., Damen I., Kaspers J., Lemckert A., van Meerendonk M., van der Vlugt R., Holterman L., Hone D., Skeiky Y., Mintardjo R., Gillissen G., Barouch D., Sadoff J., Goudsmit J. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J. Gen. Virol. 2006, 87:2135-2143.
29. Havenga M.J., Lemckert A.A., Ophorst O.J., van Meijer M., Germeraad W.T., Grimbergen J., van Den Doel M.A., Vogels R., van Deutekom J., Janson A.A., de Bruijn J.D., Uytdehaag F., Quax P.H., Logtenberg T., Mehtali M., Bout A. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 2002, 76:4612-4620.
30. He X.S., Draghi M., Mahmood K., Holmes T.H., Kemble G.W., Dekker C.L., Arvin A.M., Parham P., Greenberg H.B. T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J. Clin. Invest. 2004, 114:1812-1819.
31. Heemskerk B., Lankester A.C., van Vreeswijk T., Beersma M.F., Claas E.C., Veltrop-Duits L.A., Kroes A.C., Vossen J.M., Schilham M.W., van Tol M.J. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J. Infect. Dis. 2005, 191:520-530.
32. Heemskerk B., Veltrop-Duits L.A., van Vreeswijk T., ten Dam M.M., Heidt S., Toes R.E., van Tol M.J., Schilham M.W. Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy. J. Virol. 2003, 77:6562-6566.
33. Hierholzer J.C. Adenoviruses in the immunocompromised host. Clin. Microbiol. Rev. 1992, 5:262-274.
34. Hochrein H., Schlatter B., O'Keeffe M., Wagner C., Schmitz F., Schiemann M., Bauer S., Suter M., Wagner H. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:11416-11421.
35. Holan V., Kohno K., Minowada J. Natural human interferon-alpha augments interleukin-2 production by a direct action on the activated IL-2-producing T cells. J. Interferon Res. 1991, 11:319-325.
36. Horowitz A., Behrens R.H., Okell L., Fooks A.R., Riley E.M. NK cells as effectors of acquired immune responses: effector CD4+ T cell-dependent activation of NK cells following vaccination. J. Immunol. 2010, 185:2808-2818.
37. Iacobelli-Martinez M., Nemerow G.R. Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses. J. Virol. 2007, 81:1305-1312.
38. Jarrossay D., Napolitani G., Colonna M., Sallusto F., Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 2001, 31:3388-3393.
39. Kadowaki N., Ho S., Antonenko S., Malefyt R.W., Kastelein R.A., Bazan F., Liu Y.J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 2001, 194:863-869.
40. Kojaoghlanian T., Flomenberg P., Horwitz M.S. The impact of adenovirus infection on the immunocompromised host. Rev. Med. Virol. 2003, 13:155-171.
41. Krug A., French A.R., Barchet W., Fischer J.A., Dzionek A., Pingel J.T., Orihuela M.M., Akira S., Yokoyama W.M., Colonna M. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004, 21:107-119.
42. Krug A., Luker G.D., Barchet W., Leib D.A., Akira S., Colonna M. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 2004, 103:1433-1437.
43. Kumagai Y., Takeuchi O., Akira S. TLR9 as a key receptor for the recognition of DNA. Adv. Drug Deliv. Rev. 2008, 60:795-804.
44. Leen A.M., Sili U., Savoldo B., Jewell A.M., Piedra P.A., Brenner M.K., Rooney C.M. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 2004, 103:1011-1019.
45. Lenaerts L., De Clercq E., Naesens L. Clinical features and treatment of adenovirus infections. Rev. Med. Virol. 2008, 18:357-374.
46. Liszewski M.K., Post T.W., Atkinson J.P. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 1991, 9:431-455.
47. Lore K., Adams W.C., Havenga M.J., Precopio M.L., Holterman L., Goudsmit J., Koup R.A. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J. Immunol. 2007, 179:1721-1729.
48. Lund J., Sato A., Akira S., Medzhitov R., Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 2003, 198:513-520.
49. Nagler A., Lanier L.L., Cwirla S., Phillips J.H. Comparative studies of human FcRIII-positive and negative natural killer cells. J. Immunol. 1989, 143:3183-3191.
50. Niehues T., Rocha V., Filipovich A.H., Chan K.W., Porcher R., Michel G., Ortega J.J., Wernet P., Gobel U., Gluckman E., Locatelli F. Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children - a Eurocord analysis. Br. J. Haematol. 2001, 114:42-48.
51. Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., Robbins P.D., Gambotto A. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 2004, 11:351-357.
52. Ophorst O.J., Kostense S., Goudsmit J., De Swart R.L., Verhaagh S., Zakhartchouk A., Van Meijer M., Sprangers M., Van Amerongen G., Yuksel S., Osterhaus A.D., Havenga M.J. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 2004, 22:3035-3044.
53. Peng W.M., Yu C.F., Allam J.P., Oldenburg J., Bieber T., Hoch J., Eis-Hubinger A.M., Novak N. Inhibitory oligodeoxynucleotides downregulate herpes simplex virus-induced plasmacytoid dendritic cell type I interferon production and modulate cell function. Hum. Immunol 2007, 68:879-887.
54. Phillips J.H., Lanier L.L. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J. Exp. Med. 1986, 164:814-825.
55. Rea D., Havenga M.J., van Den A.M., Sutmuller R.P., Lemckert A., Hoeben R.C., Bout A., Melief C.J., Offringa R. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 2001, 166:5236-5244.
56. Russell W.C. Adenoviruses: update on structure and function. J. Gen. Virol. 2009, 90:1-20.
57. Schilham M.W., Claas E.C., van Zaane W., Heemskerk B., Vossen J.M., Lankester A.C., Toes R.E., Echavarria M., Kroes A.C., van Tol M.J. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin. Infect. Dis. 2002, 35:526-532.
58. Schoenly K.A., Weiner D.B. Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform spotty business. J. Virol. 2008, 82:3166-3180.
59. Segerman A., Mei Y.F., Wadell G. Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines. J. Virol. 2000, 74:1457-1467.
60. Smith C.A., Woodruff L.S., Rooney C., Kitchingman G.R. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum. Gene Ther. 1998, 9:1419-1427.
61. Tomasec P., Wang E.C., Groh V., Spies T., McSharry B.P., Aicheler R.J., Stanton R.J., Wilkinson G.W. Adenovirus vector delivery stimulates natural killer cell recognition. J. Gen. Virol. 2007, 88:1103-1108.
62. van Tol M.J., Kroes A.C., Schinkel J., Dinkelaar W., Claas E.C., Jol-van der Zijde C.M., Vossen J.M. Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. Bone Marrow Transplant. 2005, 36:39-50.
63. Veltrop-Duits L.A., Heemskerk B., Sombroek C.C., van Vreeswijk T., Gubbels S., Toes R.E., Melief C.J., Franken K.L., Havenga M., van Tol M.J., Schilham M.W. Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus. Eur. J. Immunol. 2006, 36:2410-2423.
64. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., Kostense S., Penders G., Helmus N., Koudstaal W., Cecchini M., Wetterwald A., Sprangers M., Lemckert A., Ophorst O., Koel B., van Meerendonk M., Quax P., Panitti L., Grimbergen J., Bout A., Goudsmit J., Havenga M. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 2003, 77:8263-8271.
65. Zandvliet M.L., Falkenburg J.H., van Liempt E., Veltrop-Duits L.A., Lankester A.C., Kalpoe J.S., Kester M.G., van der Steen D.M., van Tol M.J., Willemze R., Guchelaar H.J., Schilham M.W., Meij P. Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. Haematologica 2010, 95:1943-1951.
66. Zhu J., Huang X., Yang Y. A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol. Ther. 2008, 16:1300-1307.
67. Zhu J., Huang X., Yang Y. NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus. J. Immunol. 2010, 185:7480-7486.